Skip to main content
SpringerLink
Log in

Bevacizumab

In First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma

  • Adis Drug Profile
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

▴ Bevacizumab, an anti-vascular endothelial growth factor recombinant humanized monoclonal antibody, directly inhibits tumor angiogenesis and hence tumor growth.

▴ First-line therapy with intravenous bevacizumab 10 mg/kg every 2 weeks plus subcutaneous interferon-α-2a 9 million international units three times weekly has been evaluated in two randomized, double-blind or open-label, multicenter phase III trials (AVOREN [n = 649] and CALGB 90206 [n = 732]).

▴ Bevacizumab combination therapy resulted in a median progression-free survival that was significantly (p ≤ 0.0001) longer than that seen with placebo plus interferon-α-2a in AVOREN (10.2 vs 5.4 months) [hazard ratio (HR) 0.63 (95% CI 0.52, 0.75)] and that seen with interferon-α-2a alone in CALGB 90206 (8.5 vs 5.2 months).

▴ Overall survival data in AVOREN and CALGB 90206 are not yet mature. In the interim overall survival analysis in AVOREN, median overall survival was 19.8 months with placebo plus interferon-α-2a, but had not yet been reached with bevacizumab plus interferon-α-2a (HR 0.79 [95% CI 0.62, 1.02; p = 0.0670]).

▴ The overall tumor response rate with bevacizumab plus interferon-α-2a was significantly (p ≤ 0.0001) higher than with placebo plus interferon-α-2a in AVOREN (31% vs 13%) and that with interferon-α-2a alone in CALGB 90206 (25.5% vs 13.1%).

▴ Subgroup analyses in AVOREN suggested that interferon-α-2a dose reductions (to manage grade ≥3 adverse events attributable to the drug) did not compromise the efficacy of combination treatment with bevacizumab plus interferon-α-2a.

▴ The addition of bevacizumab to interferon-α-2a in AVOREN was generally well tolerated. No unexpected/new adverse events were observed; bevacizumab-associated toxicities were generally of mild intensity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Mancuso A, Stemberg CN. New treatment approaches in metastatic renal cell carcinoma. Curr Opin Urol 2006 Sep; 16(5): 337–41

    Article  PubMed  Google Scholar 

  2. Alexandrescu DT, Dasanu CA. Kidney cancer therapy: new perspectives and avenues. Expert Opin Pharmacother 2006; 7(18): 2481–93

    Article  PubMed  CAS  Google Scholar 

  3. Prasad SR, Humphrey PA, Catena JA, et al. Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics 2006; 26(6): 1795–810

    Article  PubMed  Google Scholar 

  4. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006 Mar 13; 94(5): 614–9

    PubMed  CAS  Google Scholar 

  5. Board RE, Thistlethwaite FC, Hawkins RE. Anti-angiogenic therapy in the treatment of advanced renal cell cancer. Cancer Treat Rev 2007 Feb; 33(1): 1–8

    Article  PubMed  CAS  Google Scholar 

  6. Escudier B. Advanced renal cell carcinoma: current and emerging management strategies. Drugs 2007; 67(9): 1257–64

    Article  PubMed  CAS  Google Scholar 

  7. Amato RJ, Jac J. Targeted anti-cancer therapies for renal cancer. Drugs 2006; 66(17): 2161–71

    Article  PubMed  CAS  Google Scholar 

  8. Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007 Mar; 57(2): 112–25

    Article  PubMed  Google Scholar 

  9. Canada AE, Kirkali Z. Current management of renal cell carcinoma and targeted therapy. Urol J 2006 Winter; 3(1): 1–14

    Google Scholar 

  10. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 97(7): 1663–71

    Article  PubMed  Google Scholar 

  11. Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007 Feb 15; 13(4): 1098–106

    Article  PubMed  CAS  Google Scholar 

  12. Hutson TE. Targeted therapy for renal cell carcinoma: a new treatment paradigm. Proc (Bayl Univ Med Cent) 2007 Jul; 20(3): 244–8

    Google Scholar 

  13. Nathan P, Chao D, Brock C, et al. The place of VEGF inhibition in the current management of renal cell carcinoma. Br J Cancer 2006 May 8; 94(9): 1217–20

    Article  PubMed  CAS  Google Scholar 

  14. Sutent 12.5 mg, 25 mg and 50 mg hard capsules. Summary of product characteristics. Sandwich: Pfizer Limited, 2007 Sep

  15. Sutent (sunitinib malate) capsules, oral [prescribing information]. New York: Pfizer Labs., 2007 Oct

  16. Nexavar 200mg film-coated tablets. Summary of product characteristics. New-bury: Bayer pic, 2007 Oct

  17. Nexavar (sorafenib) tablets 200 mg [prescribing information]. West Haven (CT): Bayer Pharmaceuticals Corporation, 2007 Oct

  18. ToriselTM Kit (temsirolimus) injection, for intravenous infusion only. Prescribing information. Philadelphia (PA): Wyeth Pharmaceuticals Inc., 2007 May

  19. Lyseng-Williamson KA, Robinson DM. Bevacizumab: a review of its use in advanced colorectal cancer, breast cancer, and NSCLC. Am J Cancer 2006; 5(1): 43–60

    Article  CAS  Google Scholar 

  20. Culy C. Bevacizumab: antiangiogenic cancer therapy. Drugs Today 2005; 41(1): 23–36

    Article  PubMed  CAS  Google Scholar 

  21. Avastin (bevacizumab). Prescribing information. San Francisco (CA): Genentech Inc., 2006 Oct

  22. Avastin 25 mg/mL concentrate for solution for infusion. Summary of product characteristics. Welwyn Garden City: Roche Products Limited, 2008

  23. Roche. Avastin approved in Europe for first-line treatment of patients with advanced kidney cancer [media release; online]. Available from URL: http://www.roche.com [Accessed 2007 Dec 31]

  24. Scott LJ. Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs 2007; 67(12): 1793–9

    Article  PubMed  CAS  Google Scholar 

  25. Croom KF, Foster RH. Bevacizumab: in the treatment of colorectal cancer. Am J Cancer 2004; 3(3): 187–94

    Article  CAS  Google Scholar 

  26. Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997 Oct 15; 57(20): 4593–9

    PubMed  CAS  Google Scholar 

  27. Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7(4): 335–45

    Article  PubMed  CAS  Google Scholar 

  28. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993 Apr 29; 362(6423): 841–4

    Article  PubMed  CAS  Google Scholar 

  29. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19(3): 843–50

    PubMed  CAS  Google Scholar 

  30. Margolin K, Gordon MS, Holmgren E, et al. Phase 1b trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001; 19(3): 851–6

    PubMed  CAS  Google Scholar 

  31. Gaudrealt J, Lieberman G, Kabbinavar F, et al. Pharmacokinetics (PK) of bevacizumab (BV) in colorectal cancer (CRC) [abstract no. PI-98]. Clin Pharmacol Ther 2001 Feb; 69(2): P25

    Google Scholar 

  32. European Medicines Agency. Avastin European Public Assessment Report: scientific discussion [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/avastin/17199204en6.pdf [Accessed 2007 Nov 30]

  33. -Mahmood I. Center for Drug Evaluation and Research. Approval package for: application number STN-125085/0 — clinical pharmacology/TOX review [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2004/STN-125085_Avastin_BioPharmr.pdf [Accessed 2007 Nov 28]

  34. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007 Oct 10; 25(29): 4536–41

    Article  PubMed  CAS  Google Scholar 

  35. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 Jul 31; 349(5): 427–34

    Article  PubMed  CAS  Google Scholar 

  36. Hainsworth JD, Sosman JA, Spigel DR, et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005 Nov 1; 23(31): 7889–96

    Article  PubMed  CAS  Google Scholar 

  37. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007 Dec 22; 370(9605): 2103–11

    Article  PubMed  Google Scholar 

  38. Rini BI, Halabi S, Taylor J, et al. Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004 Apr 15; 10(8): 2584–6

    Article  PubMed  CAS  Google Scholar 

  39. Phase III randomized study of interferon alfa-2b with or without bevacizumab in patients with advanced renal cell carcinoma. Identifier: NCT00072046 [online]. Available from URL: http://clinicaltrials.gov/ct/show/NCT00072046 [Accessed 2008 Feb 27]

  40. Escudier B, Koralewski P, Pluzanska A, et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-alpha-2a vs placebo/interferon-alpha-2a as first-line therapy in metastatic renal cell carcinoma [abstract no. 3]. J Clin Oncol 2007 Jun 20; 25 (18S Pt I): 2s–5. Plus oral presentation at the 2007 American Society of Clinical Oncology Annual Meeting; 2007 Jun 1

    Google Scholar 

  41. Bracarda S, Koralewski P, Pluzanska A, et al. Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN) [abstract no. 4008]. EJC Supplements 2007 Sep; 5(4): 281–2. Plus poster presented at the 2007 European Cancer Conference; 2007 Sep 23–27; Barcelona

    Google Scholar 

  42. Melichar B, Koralewski P, Pluzanska A, et al. First-line bevacizumab improves progression-free survival with lower doses of interferon-alpha-2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN) [abstract no. 4518]. EJC Supplements 2007 Sep; 5(4): 304. Plus poster presented at the 2007 European Cancer Conference; 2007 Sep 23–27; Barcelona

    Google Scholar 

  43. Rini BI, Halabi S, Rosenberg JE, et al. CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma [abstract no. 350]. Plus oral and poster presentations at the 2008 Genitourinary Cancers Symposium; 2008 Feb 14–16; San Francisco (CA) [online]. Available from URL: http://www.asco.org [Accessed 2008 Feb 27]

  44. Phend C. Medical news from ASCO GU: bevacizumab-based duo retards metastatic kidney cancer [online]. Available from URL: http://www.medpagetoday.com [Accessed 2008 Feb 27]

  45. Sanborn RE, Sandler AB. The safety of bevacizumab. Expert Opin Drug Saf 2006; 5(2): 289–301

    Article  PubMed  CAS  Google Scholar 

  46. Los M, Roodhart JML, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007; 12: 443–50

    Article  PubMed  CAS  Google Scholar 

  47. Feldman DR, Kondagunta GV, Ronnen EA, et al. Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 2007 Jun 20; 25 (18S Pt 1): 5099

    Google Scholar 

  48. Sosman JA, Flaherty K, Atkins MB. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (pts). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings 2006 Jun 20; 24 (18S Pt 1): 3031

    Google Scholar 

Download references

Acknowledgments and Disclosures

The manuscript was reviewed by: R.M. Bukowski, Cleveland Clinic Foundation, Cleveland, Ohio, USA; J. Medioni, Georges Pompidou European Hospital, Paris, France; P. Nathan, Mount Vernon Cancer Centre, Northwood, England.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Wolters Kluwer Health ¦ Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    James E. Frampton & Gillian M. Keating

  2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    James E. Frampton & Gillian M. Keating

Authors
  1. James E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Frampton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frampton, J.E., Keating, G.M. Bevacizumab. BioDrugs 22, 113–120 (2008). https://doi.org/10.2165/00063030-200822020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200822020-00004

Keywords

Search

Navigation